Stay updated with breaking news from Mark Mintun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brits should be able to get the new Alzheimer's drug donanemab which can slow the disease to a crawl in the next two years with experts urging regulators to do all they can to approve the treatment.
A breakthrough - donanemab has emerged as a significant milestone in the battle against Alzheimer's after a global trial confirmed its ability to slow down cognitive decline. Made by US pharmaceuticals group Eli Lilly, the results of a clinical trial to showcase the findings said antibody treatment slowed progression by about 35 per cent in the early stages of the disease, allowing people with Alzheimer’s to continue performing day-to-day tasks such as shopping, housekeeping, managing their finances and taking medication. , Health News, Times Now
A new drug has been hailed as a "turning point in the fight against Alzheimer's" after it was found to slow the progression of the…
New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more
WASHINGTON (AP) — Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.